Summary of transaction
Randy Teel, president and chief executive officer of Arvinas, Inc. (NASDAQ: ARVN), sold a combined 4,786 shares of common stock on February 23, 2026, for an aggregate amount of approximately $58,197. The shares were sold at $12.16 apiece, which is below the company’s current quoted stock price of $13.30. According to records, this sale occurred through two separate transactions of 1,038 shares and 3,748 shares respectively, as disclosed in a Form 4 filing with the Securities and Exchange Commission.
Nature of the sales
The Form 4 indicates these dispositions were executed automatically to cover tax withholding obligations arising from the vesting and settlement of restricted stock units. The filing specifies these were not discretionary trades by the executive. After completion of the transactions, Teel directly holds 149,696 shares of Arvinas common stock.
Market context and valuation notes
Market data referenced in accompanying analysis show the stock has delivered strong momentum, returning 76% over the past six months. A Fair Value assessment cited alongside that momentum characterizes the company as appearing undervalued. Those valuation metrics are presented in the same data set that tracks the momentum figure.
Recent financial performance
Arvinas reported fourth-quarter 2025 results that fell short of consensus forecasts. The company posted an earnings per share of -$1.10, missing the expected -$0.51. Revenue for the period was $9.5 million, compared with an anticipated $36.92 million, representing a 74.27% shortfall relative to expectations.
Analyst update
Following the release of results, Wedbush adjusted its target price for Arvinas to $11 from $9 and maintained a Neutral rating on the shares. The firm called out progress on Arvinas’ LRRK2 degrader ARV-102, which the company has on track for presentation at an upcoming conference scheduled for March 2026.
Research resources
Investors seeking deeper financial and corporate analysis are directed to a Pro Research Report that covers Arvinas alongside more than 1,400 other U.S. equities. That research source is listed as available for those who wish to examine the company’s financial condition and executive actions in more detail.
The transactions and the company’s recent operational and financial updates together paint a picture of a biotechnology company navigating mixed signals - strong share momentum and valuation indications on one hand, and significant quarterly revenue and earnings shortfalls on the other. The executive sale was an automatic, tax-related event tied to RSU settlement and did not represent a discretionary disposal of shares.